Drug intelligence / Profile preview

ZE00-0388

Development stage: Preclinical
Lead developer: Mondego Bio
Modality: Small Molecules
Administration: Oral

Overview

ZE00-0388 is an AI-designed, highly selective small-molecule inhibitor of Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2). Developed by Mondego Bio, a Lisbon-based immuno-oncology company, the drug acts as a negative regulator of the JAK-STAT pathway, which is a critical mediator of immune regulation within the tumor microenvironment. By inhibiting PTPN2, ZE00-0388 is intended to overcome immune suppression and enhance anti-tumor responses. The candidate is being developed for the treatment of solid tumors, with plans for evaluation as both a monotherapy and in combination with immune checkpoint inhibitors. A first-in-human Phase 1 clinical trial is scheduled to commence in the first half of 2026.

Other names: PTPN2/PTPN1 inhibitor

Targets

PTPN1 (Protein tyrosine phosphatase 1B)PTPN2

Beyond the preview

Go deeper on ZE00-0388.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZE00-0388.

Explore the full profile